Reduction of unnecessary antibiotic days in a level IV neonatal intensive care unit

Dipen P. Vyas MD1, Vilmaris Quinones-Cardona MD1, Margaret A. Gilfillan MD1, Megan E. Young PharmD, BCPS1,2, Kimberly A. Pough PharmD1,2, and Alison J. Carey MD1,3

1Pediatrics, St. Christopher’s Hospital for Children, Drexel University College of Medicine, Philadelphia, Pennsylvania, 2Department of Pharmacy, St. Christopher’s Hospital for Children, Philadelphia, Pennsylvania and 3Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania

Abstract

Objective: Antibiotics are widely prescribed in the neonatal intensive care unit (NICU) and duration of prescription is varied. We sought to decrease unnecessary antibiotic days for the most common indications in our outborn level IV NICU by 20% within 1 year.

Design and interventions: A retrospective chart review was completed to determine the most common indications and treatment duration for antibiotic therapy in our 39-bed level IV NICU. A multidisciplinary team was convened to develop an antibiotic stewardship quality improvement initiative with new consensus guidelines for antibiotic duration for these common indications. To optimize compliance, prospective audit was completed to ensure antibiotic stop dates were utilized and provider justification for treatment duration was documented. Multiple rounds of educational sessions were conducted with neonatology providers.

Results: In total, 262 patients were prescribed antibiotics (139 in baseline period and 123 after the intervention). The percentage of unnecessary antibiotic days (UAD) was defined as days beyond the consensus guidelines. As a balancing measure, reinitiation of antibiotics within 2 weeks was tracked. After sequential interventions, the percentage of UAD decreased from 42% to 12%, which exceeded our goal of a 20% decrease. Compliance with antibiotic stop dates increased from 32% to 76%, and no antibiotics were reinitiated within 2 weeks.

Conclusions: A multidisciplinary antibiotic stewardship team coupled with a consensus for antibiotic therapy duration, prescriber justification of antibiotic necessity and use of antibiotic stop dates can effectively reduce unnecessary antibiotic exposure in the NICU.

(Received 12 October 2021; accepted 11 February 2022)
Baseline period and identification of primary drivers for unnecessary antibiotic prescription

Baseline data from January 1, 2019, to December 31, 2019, were collected retrospectively. Through analysis of retrospective data and focus group discussions with providers, the primary reasons for UADs were identified and a fishbone diagram was created (Fig. 1). The most common reason for prolonged antibiotic therapy was fear of treatment failure and complexity of the patient population, such as those on extracorporeal membrane oxygenation or therapeutic hypothermia. In addition, despite having a hospital-wide antibiotic stewardship team, with pharmacy and infection prevention expertise, there was no coordinated effort focused on neonatal antibiotic stewardship. Therefore, a NICU-specific multidisciplinary antimicrobial stewardship team was needed. A team of a neonatal fellow, neonatal nurse practitioner, neonatology attending, infectious disease attending, NICU-specific clinical pharmacist and an antimicrobial stewardship pharmacist was formed and convened in December 2019 to review the baseline data and develop targeted interventions. The following primary drivers were identified to achieve a reduction in UADs: (1) to ensure adherence to the 7 core elements of Center for Disease Control and Prevention (CDC) hospital antibiotic stewardship program (ie, hospital leadership commitment, accountability, pharmacy expertise, action, tracking, reporting, and education); (2) to increase awareness and engage frontline neonatology healthcare workers about NICU antibiotic stewardship; and (3) to address the need for multidisciplinary input (Fig. 2).

Interventions

Over the course of the study period, 5 specific interventions to address these drivers were implemented to achieve the primary aim. We used the Institute for Healthcare Improvement’s Model for Improvement for this initiative and plan-do-study-act (PDSA) cycles to assess our progress (Fig. 3)15. Discussions were inconsistent regarding justification for the initiation (indication), continuation, and duration of antibiotic use during rounds, with tremendous inter-prescriber variability. To increase awareness and engage NICU providers about antibiotic stewardship, a consensus guideline for therapy duration was developed, manual antibiotic stop dates were implemented, justification of antibiotic use was requested, and a series of educational sessions were conducted.

In our level IV unit, a NICU-specific clinical pharmacist is present on rounds 5 days a week who encouraged justification and verbal timeouts during rounds. In addition, the antibiotic stewardship pharmacist provided prospective audit and feedback.

Consensus guideline for duration of therapy

In the retrospective data review, the most common indications for antibiotic prescription were (1) rule out sepsis, (2) culture-negative sepsis, and (3) respiratory tract infection (tracheitis and pneumonia). In addition, we noted wide variation in antibiotic duration for each indication between providers. During the baseline period, treatment to rule out sepsis had a duration of 2–3 days, treatment for culture-negative sepsis had a duration of 5–14 days, treatment for tracheitis had a duration of 5–7 days, and treatment for pneumonia had a duration of 7–10 days, based on provider preference. Thus, based on this wide variation, interventions focused on the development of consensus guidelines for these (ie, most common) indications of antibiotic use. Available evidence was reviewed to develop appropriate therapy duration for these indications, and a consensus was determined by the division and presented during an educational conference on January 14, 2020, (Table 1). Based on this consensus, we adopted standardized duration of therapy of 48 hours to rule out sepsis, 5 days for culture-negative sepsis and tracheitis, and 7 days for uncomplicated pneumonia.

Manual antibiotic stop dates

Our retrospective analysis revealed that antibiotics were unnecessarily prolonged because there was a delay in manual discontinuation of antibiotics. Automatic duration of therapy or a hard stop on specific antibiotics were considered but could not be implemented because the electronic health record (EHR) system did not have this feature. Therefore, to avoid delay in antibiotic discontinuation, antibiotic orders were required to have a manually entered stop date (Supplementary Fig. 1). This intervention began on January 1, 2020.

Justification of antibiotic use and verbal time outs

Providers were encouraged to have discussions during daily rounds about indications and duration for continued antibiotic use. Documentation of this discussion in the daily progress note was requested. If there was a decision to prescribe a patient an antibiotic
therapy course longer than consensus guidelines, justification was required in the daily progress note. Starting April 1, 2020 (PDSA 2), the clinical pharmacist performed a verbal time-out on rounds 24–48 hours after antibiotic initiation for every patient prescribed antibiotics. Time-outs included defining the indication for antibiotic use, appropriate duration of therapy and potential narrowing of antibiotic therapy. This process was performed daily until all questions were documented in the progress note.

**Education of the providers**

Several educational sessions were held to discuss consensus guidelines, to reinforce the importance of antibiotic stop dates, and to request documentation of justification of antibiotics for all the neonatology fellows, neonatology attending physicians, neonatal nurse practitioners, and nurses. Fellow educational conferences were used as opportunities for education of the neonatal fellows and attending physicians (Table 1). In addition, small group discussions were performed with neonatal fellows and rotating residents in the NICU at the start of their rotation to update them on the interventions. Antibiotic choice was not a focus of this initiative.

**Prospective audit and feedback**

Antibiotic stewardship, pharmacist-driven, prospective audit and feedback began on January 14, 2020. The antibiotic stewardship
pharmacist was responsible to perform a daily screen of antibiotic duration and stop dates in the EHR for any patients on antibiotics >48 hours. Antibiotic duration was considered prolonged if it was longer than the consensus guidelines. If there was prolonged antibiotic duration or was no stop date, the stewardship pharmacist called the neonatology fellow, pediatric resident physician, or advanced practitioner in the NICU to provide real-time feedback. Ultimately, the final decision for the antibiotic duration was at the primary team’s discretion.

Outcomes

The primary outcome was percentage of patients with UADs per 2-week interval. UADs were defined as therapy duration beyond the consensus guidelines. All antibiotic orders were reviewed for compliance with inclusion of a stop date. Total number of stop dates ordered was tracked as a percentage of total number of patients initiated on antibiotics each month. For percentage of justification of antibiotic use, progress notes of only those patients who had UADs and 5 other randomly selected progress notes were reviewed retrospectively every month for documentation of why antibiotics were initiated, indication, duration of therapy, and reason therapy was longer than the consensus guidelines if there were UADs.

The antibiotic stewardship pharmacist performed prospective audit and feedback for prolonged therapy duration, and the total number of feedback sessions was tracked as a percentage of total number of patients initiated on antibiotics each month. The most frequent reason that the focus group (the neonatal attending, fellows, and nurse practitioners) cited to not decrease duration of antibiotics was failure of therapy. Therefore, we tracked reinitiation of antibiotics for any indication within 2 weeks of onset of antibiotic prescription as a balancing measure.

Statistical analysis

Descriptive analysis was conducted for gestational age, birth weight, any antibiotic exposure and antibiotic use for each indication. A descriptive analysis and Pearson $\chi^2$ test were performed with statistical package for social sciences using SPSS version 24 software (IBM, Armonk NY). The outcome, process and balancing measures were displayed using statistical process control (SPC) P and X bar and S charts. QI-Macros 2020 software was used to analyze and generate SPC charts. Centerlines and $\Delta$ (delta) control limits were applied when at least 8 consecutive points were above or below the center line, when 1 or more data points fell beyond the control limits, or when 6 consecutive points comprised a trend in either direction.$^{16,19}$ Centerlines were adjusted based on detection of special cause signal.$^{36}$ Ethical aspects of the interventions and studying of interventions was reviewed by local institutional review board and was exempt from consent by the Internal Review Board of Drexel University College of Medicine (IRB 2012008285, February 11, 2021).
Results
Antibiotic prescription in the NICU
During the study period, 514 neonates were admitted to the NICU. Of these, 250 were admitted during the baseline period (January 1, 2019, to December 31, 2019) and 264 were admitted during the postintervention period (January 1, 2020, to February 28, 2021). Charts were reviewed for exposure to at least 1 antibiotic prior to discharge, noted as antibiotic exposures. In total, 139 (55%) of 250 neonates were exposed to at least 1 antibiotic in the baseline period compared to 123 (46%) of 264 in the postintervention period. Of these antibiotic-exposed neonates, 90 (65%) of 139 in the baseline period and 86 (70%) of 123 in the postintervention period were treated with antibiotics for the most common indications (ie, rule out sepsis, culture negative sepsis, and respiratory tract infection) (Table 2). Birth weight and gestational age were comparable between the 2 periods. We observed significant variability of the age of the neonate at the time antibiotics were initiated, based on the diagnosis.

Reduction of unnecessary antibiotic days after implementation of consensus guidelines, antibiotic stop dates and improved justification
After 3 PDSA cycles (Fig. 3), we noted a special cause variation, defined by 8 consecutive points below the centerline, with a decrease in the average percentage of patients with UAD from 42% to 12% (Fig. 4). Special cause variation was also noted with 1 data point above the upper control limit during the 2-week interval of January 16, 2020–January 31, 2020. During this time, only 3 patients were on antibiotics, which was fewer than during other intervals. Also, 2 of these patients had a complicated clinical course with worsening acute on chronic pulmonary hypertension, and the third patient was on extracorporeal membrane oxygenation, which prompted the primary team to treat longer based on clinical presentation. This data point was included in the center-line calculation to avoid a false reduction in the percentage of patients with UAD.

We observed special cause variation in the percentage of antibiotic stop dates used, which increased from 32% to 76% (Fig. 5A). Documentation of justification of antibiotic use improved, with an increase from 24% to 90% and special cause variation (Fig. 5B). Prospective audit and antibiotic stewardship feedback was performed in 20% of total patients on antibiotics by antibiotic stewardship pharmacist during the postintervention period. Importantly, no change occurred in the average percentage of reinitation of antibiotics per month.

Discussion
In a level IV NICU with a medically complex outborn population, there can be considerable variability in antibiotic prescription duration. Therefore, standardized guidelines for antibiotic duration must be developed for appropriate antimicrobial stewardship in this unique population. Here, a comprehensive approach for antibiotic stewardship to safely reduce UAD at a level IV NICU was achieved through the creation of a NICU-specific multidisciplinary antibiotic stewardship team, standardized duration of therapy for the most common antibiotic indications, antibiotic stop dates and prospective audit and feedback.

Although antibiotic stewardship strategies have been described in the neonatal population, literature is limited regarding stewardship initiatives specifically in NICUs that care for the most critically ill neonates. Antibiotic stewardship interventions have
focused on shortening the duration of antibiotic therapy, reduction of initiation of antibiotic therapy, and infrastructural antibiotic stewardship program implementation. Here, we employed 2 of these key components: reduction of the duration of antibiotic therapy through consensus guidelines and the creation of a NICU-specific antibiotic stewardship program. Reduction of initiation of antibiotic therapy, such as the use of an early-onset, sepsis-risk calculator, can reduce antibiotic

Fig. 5. Process measures. The p-chart for (A) monthly documentation justifying antibiotic use in the daily progress notes and (B) percentage of antibiotic stop dates used per month.
exposure in infants >35 weeks gestational age in the delivery hospital setting.\textsuperscript{28,29} However, this model is less practical in our medical complex term or preterm infants, who frequently have been initiated on antibiotics by the referring institution.

Identification of strategies that could be both safely and effectively applied to a level IV NICU population was of particular importance in this antibiotic stewardship initiative. Several strategies have been applied to reduce the duration of antibiotics in high-acuity inborn NICUs, including antibiotic hard stops\textsuperscript{22,23} and standardized duration of therapy for common indications\textsuperscript{16} and prospective audit and feedback.\textsuperscript{14} Here, we applied these interventions in an outborn level IV NICU with some unit-specific modifications. We encountered infrastructure difficulties in making changes in the EHR to implement automatic antibiotic stop dates. Therefore, provider education to manually enter stop dates at the time of antibiotic prescription was completed. Although manual entry of stop dates was more labor intensive, this approach was effective in reducing the percentage of patients with UAD in our NICU, as demonstrated by others,\textsuperscript{16} and this strategy could be utilized by other centers with similar EHR restrictions.

The development of a consensus guideline for duration of therapy targeted at the indications mostly commonly used in the NICU was an important component of effectively reducing UAD. Developing evidence-based guidelines with infectious disease input was key to engage the neonotologists and create consensus. Given the clinical severity and complexity of our patients, our interventions centered on a team-based approach to provider education with real-time discussions and feedback, while affording neonotologists the autonomy to initiate and select antibiotics of their choice. Ultimately, this autonomy improved acceptance of the consensus guidelines and drove culture change.

Similar to central-line–associated bloodstream infection reduction initiatives,\textsuperscript{30} a successful component of our initiative was requesting daily documentation to justify antibiotic prescription. The clinical pharmacist conducted a verbal time-out during daily rounds if antibiotics remained necessary and discussed opportunities to narrow therapy and planned duration. This particular intervention is consistent with the tenet of accountability in the CDC Core Elements of Hospital Antibiotic Stewardship Programs.\textsuperscript{14} A recent multicenter national quality improvement project of the Vermont Oxford Network reduced antibiotic use by 34% with improved adherence to several of the CDC Core Elements. \textsuperscript{31} Similarly, we were successful in reducing the percentage of patients with UADs by 70% with our multipronged approach.

This study had several limitations. The initiative was conducted at a single-center NICU. Therefore, generalizability may be limited to level IV NICUs with a similar patient population and a full complement of resources, such as a dedicated clinical pharmacist present during daily rounds. Furthermore, the scope of this initiative was limited to the most common indications for antibiotic use. Culture-proven infection of blood and urinary tract were rare during this epoch. Our consensus guidelines focused on treatment for either culture-negative sepsis or positive respiratory cultures, which frequently reflect colonization. Further work should explore treatment duration for culture-proven infections in the most vulnerable patients with immature immune systems, especially in the first weeks after birth.

A multidisciplinary antibiotic stewardship team coupled with focused interventions including the use of standardized duration of therapy, antibiotic justification, stop dates, and prospective audit and feedback can effectively and safely reduce UAD in an outborn level IV NICU. Future PDSA cycles will expand the breadth of this initiative to other antibiotic indications and will facilitate strategies that focus on reducing antibiotic initiation to further decrease UAD in our NICU.

**Supplementary material.** To view supplementary material for this article, please visit https://doi.org/10.1017/ash.2022.33

**Acknowledgment.** We acknowledge the efforts of all members of the neonatology team including the attending neonotologists, fellows, residents, nurse practitioners, and registered nurses at St. Christopher’s Hospital for Children. In addition, we acknowledge Dr. Ishminder Kaur and Dr. Emily Souder for their infectious disease expertise, specifically with the creation of the consensus antibiotic therapy guidelines.

**Financial support.** This work was supported by the Neonatology Research and Education Fund from the St. Christopher’s Hospital for Children Foundation.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

**References**

1. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. *Pediatrics* 2006;117:1979–1987.
2. Hsieh EM, Hornik CP, Clark RH, et al. Medication use in the neonatal intensive care unit. *Am J Perinatol* 2014;31:811–821.
3. Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. *JAMA* 2015;314:1039–1051.
4. Jiang S, Yang Z, Shan R, et al. Neonatal outcomes following culture-negative late-onset sepsis among preterm infants. *Pediatr Infect Dis J* 2020;39:232–238.
5. Raymond SL, Rincon JC, Wynn JL, Moldawer LL, Larson SD. Impact of early-life exposures to infections, antibiotics, and vaccines on perinatal and long-term health and disease. *Front Immunol* 2017;8:729.
6. Ting JY, Roberts A, Sherlock R, et al. Duration of initial empirical antibiotic therapy and outcomes in very low birth weight infants. *Pediatrics* 2019;143(3):e20182286.
7. Mukhopadhyay S, Puopolo KM, Hansen NI, et al. Impact of early-onset sepsis and antibiotic use on death or survival with neurodevelopmental impairment at 2 years of age among extremely preterm infants. *J Pediatr* 2020;221:39–46.
8. Hooven TA, Randis TM, Polin RA. What’s the harm? Risks and benefits of evolving rule-out sepsis practices. *J Perinatol* 2018;38:614–622.
9. Tsai MH, Chu SM, Hsu JF, et al. Risk factors and outcomes for multidrug-resistant gram-negative bacteria in the NICU. *Pediatrics* 2014;133:e322–e329.
10. Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birthweight infants. *Pediatrics* 2006;118:717–722.
11. Kummeling I, Stelma FF, Dagnelie PC, et al. Early life exposure to antibiotics and the subsequent development of eczema, wheeze, and allergic sensitization in the first 2 years of life: the KOALA Birth Cohort Study. *Pediatrics* 2007;119(1):e225–e231.
12. Risnes KR, Belanger K, Murk W, Bracken MB. Antibiotic exposure by 6 months and asthma and allergy at 6 years: findings in a cohort of 1,401 US children. *Am J Epidemiol* 2011;173:310–318.
13. Saati A, Virta LJ, Sankilampi U, Dunkel L, Saxen H. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. *Pediatrics* 2015;135:617–626.
14. Core elements of hospital antibiotic stewardship programs. Centers for Disease Control and Prevention website. [https://www.cdc.gov/antibiotic-use/core-elements/hospital.html](https://www.cdc.gov/antibiotic-use/core-elements/hospital.html). Published 2019. Accessed March 4, 2022.
15. Langley GL, MR, Nolan KM, Nolan TW, Norman CL, Provost LP. *The Improvement Guide: A Practical Approach to Enhancing Organizational Performance*, 2nd edition. Hoboken, NJ: Jossey-Bass; 2009.
16. Cantey JB, Wozniak PS, Pruszynski JE, Sanchez PJ. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study. *Lancet Infect Dis* 2016;16:1178–1184.
17. Hemels MA, van den Hoogen A, Verboon-Maciolek MA, Fleer A, Krediet TG. Shortening the antibiotic course for the treatment of neonatal coagulase-negative staphylococcal sepsis: fine with three days? *Neonatology* 2012;101:101–105.
18. Benneyan JC, Lloyd RC, Pylek PE. Statistical process control as a tool for research and healthcare improvement. *Qual Saf Health Care* 2003;12:458–464.
19. Loyd PP, Sandra KM. *The Health Care Data Guide: Learning From Data For Improvement*, first edition. San Francisco, CA: Jossey-Bass; 2011.
20. Cheung YY, Jung B, Sohn JH, Ogirnc G. Quality initiatives: statistical control charts simplifying the analysis of data for quality improvement. *Radiographics* 2012;32:2113–2126.
21. Bhat R, Custodio H, McCurley C, et al. Reducing antibiotic utilization rate in preterm infants: a quality improvement initiative. *J Perinatol* 2018;38:421–429.
22. Astorga MC, Piscitello KJ, Menda N, et al. Antibiotic stewardship in the neonatal intensive care unit: effects of an automatic 48-hour antibiotic stop order on antibiotic use. *J Pediatric Infect Dis Soc* 2019;8:310–316.
23. Tolia VN, Desai S, Qin H, et al. Implementation of an automatic stop order and initial antibiotic exposure in very low birthweight infants. *Am J Perinatol* 2017;34:105–110.
24. Kitano T, Takagi K, Arai I, et al. A simple and feasible antimicrobial stewardship program in a neonatal intensive care unit of a Japanese community hospital. *J Infect Chemother* 2019;25:860–865.
25. Tagare A, Kadam S, Vaidya U, Pandit A. Routine antibiotic use in preterm neonates: a randomised controlled trial. *J Hosp Infect* 2010;74:332–336.
26. Lu C, Liu Q, Yuan H, Wang L. Implementation of the smart use of antibiotics program to reduce unnecessary antibiotic use in a neonatal ICU: a prospective interrupted time-series study in a developing country. *Crit Care Med* 2019;47(1):e1–e7.
27. McCarthy KN, Hawke A, Dempsey EM. Antimicrobial stewardship in the neonatal unit reduces antibiotic exposure. *Acta Paediatr* 2018;107:1716–1721.
28. Zayek M, Bhat J, Bonner K, et al. Implementation of a modified neonatal early-onset sepsis calculator in well-baby nursery: a quality improvement study. *Pediatr Qual Saf* 2020;5(4):e330.
29. Dhudasia MB, Mukhopadhyay S, Puopolo KM. Implementation of the sepsis risk calculator at an academic birth hospital. *Hosp Pediatr* 2018;8:243–250.
30. Li S, Faustino EV, Golombek SG. Reducing central-line infections in pediatric and neonatal patients. *Curr Infect Dis Rep* 2013;15:269–277.
31. Dukhovny D, Buus-Frank ME, Edwards EM, et al. A collaborative multi-center QI initiative to improve antibiotic stewardship in newborns. *Pediatrics* 2019;144(6). doi: 10.1542/peds.2019-0589.